The fact that migraine therapy is changing is also reflected in the recent publication of the updated S1 guideline “Treatment of migraine attacks and prophylaxis of migraine”. Although triptans are still the standard medication for treating acute migraine attacks, new active ingredients are expanding the treatment arsenal. Progress has also been made in migraine prophylaxis – for example, two new oral CGRP receptor antagonists have established themselves as treatment alternatives. These are just some of the innovations that should contribute to optimized care for migraine patients.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- Patient-centered rounds in medicine
Aligning care with the patient
- Adrenogenital syndrome
Clinical care from birth to adulthood
- Communication between hospitals and outpatient care
How does a digital clinical information system prove itself in everyday practice?
- Acute myeloid leukemia
Treatment decisions between MRD monitoring, transplantation and CAR-T cells
- Psoriasis and metabolic comorbidities: new study data
GLP-1RAs showed a valuable dual benefit
- Heart failure: combination of four as "Guideline-Directed Medical Therapy"
Standard established at HFrEF with individual nuances
- Chronic inflammation as a driver of ageing
Immunosenescence and inflammaging
- Evidence, limitations and practical implications